CLD50 Engaged in Inhaled Nitric Oxide Breakthrough

Cambustion are pleased to share the news of a major breakthrough in inhaled high-dose nitric oxide therapy, aided by the use of the CLD50 Fast NO and NO2 analyzer.

Work conducted at Massachusetts General Hospital has shown that inhaled high-dose nitric oxide (NO) has potential antimicrobial activity against bacteria, viruses and fungi with no adverse effects. This offers future treatment avenues for antibiotic resistant respiratory infections.

The CLD50 was used to measure live breath-by-breath concentrations of NO and NO2, for determining absorbed NO between inhalation and exhalation, as well as ensuring patient safety by quantifying NO2 exposure.

For more information, please get in touch at cambustion@cambustion.com

Link to paper: https://www.science.org/doi/10.1126/scitranslmed.ady2646